Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial)

被引：22
|
作者：
Chanan-Khan, A. [1 ]
Egyed, M. [2 ]
Robak, T. [3 ]
Martinelli de Oliveira, F. A. [4 ]
Echeveste, M. A. [5 ]
Dolan, S. [6 ]
Desjardins, P. [7 ]
Blonski, J. Z. [3 ]
Mei, J. [8 ]
Golany, N. [8 ]
Zhang, J. [8 ]
Gribben, J. G. [9 ]
机构：
[1] Mayo Clin, Div Hematol & Oncol, Jacksonville, FL 32224 USA
[2] Kaposi Mor Oktato Korhaz, Dept Internal Med, Kaposvar, Hungary
[3] Med Univ Lodz, Dept Hematol, Lodz, Poland
[4] Hosp Erasto Gaertner, Dept Oncol, Curitiba, Parana, Brazil
[5] Hosp Univ Donostia, Hematol Serv, San Sebastian, Spain
[6] St Johns Hosp, Div Hematol, St John, NB, Canada
[7] Hosp Charles LeMoyne, Dept Hematol, Greenfield Pk, PQ, Canada
[8] Celgene Corp, Summit, NJ USA
[9] Barts Canc Inst, Ctr Haemato Oncol, London, England
来源：
LEUKEMIA | 2017年 / 31卷 / 05期
关键词：
D O I：
10.1038/leu.2017.47
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1240 / 1243
页数：5
相关论文
共 50 条
  • [1] Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial)
    A Chanan-Khan
    M Egyed
    T Robak
    F A Martinelli de Oliveira
    M A Echeveste
    S Dolan
    P Desjardins
    J Z Blonski
    J Mei
    N Golany
    J Zhang
    J G Gribben
    Leukemia, 2017, 31 : 1240 - 1243
  • [2] Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial
    Robak, T
    Blonski, JZ
    Kasznicki, M
    Blasinska-Morawiec, M
    Krykowski, E
    Dmoszynska, A
    Mrugala-Spiewak, H
    Skotnicki, AB
    Nowak, W
    Konopka, L
    Ceglarek, B
    Maj, S
    Dwilewicz-Trojaczek, J
    Heilmann, A
    Urasinski, I
    Zdziarska, B
    Kotlarek-Haus, S
    Potoczek, S
    Grieb, P
    BLOOD, 2000, 96 (08) : 2723 - 2729
  • [3] Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia
    Hillmen, Peter
    Skotnicki, Aleksander B.
    Robak, Tadeusz
    Jaksic, Branimir
    Dmoszynska, Anna
    Wu, Jingyang
    Sirard, Cynthia
    Mayer, Jiri
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (35) : 5616 - 5623
  • [4] Comparison the Survival Rate of Fludarabine, Chlorambucil and Cyclophosphamide as First-Line Therapy in Patients with Chronic Lymphocytic Leukemia
    Sedaghat, Sadegh
    Montazeri, Maryam
    Rashidi, Negin
    Montazeri, Mahdi
    Montazeri, Mohammad
    ANNALS OF MEDICAL AND HEALTH SCIENCES RESEARCH, 2018, 8 (01) : 99 - 104
  • [5] First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial
    Moreno, Carol
    Greil, Richard
    Demirkan, Fatih
    Tedeschi, Alessandra
    Anz, Bertrand
    Larratt, Loree
    Simkovic, Martin
    Novak, Jan
    Strugov, Vladimir
    Gill, Devinder
    Gribben, John G.
    Kwei, Kevin
    Dai, Sandra
    Hsu, Emily
    Dean, James P.
    Flinn, Ian W.
    HAEMATOLOGICA, 2022, 107 (09) : 2108 - 2120
  • [6] First-Line Therapy for Chronic Lymphocytic Leukemia
    Cherng, Hua-Jay J.
    Jain, Nitin
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2021, 35 (04) : 725 - 738
  • [7] Efficacy and Safety of First-Line Therapy with Chlorambucil, Rituximab and Individualized Dose Lenalidomide in FCR-Unfit Patients with Advanced Chronic Lymphocytic Leukemia (CLL): A Phase I/II HOVON Trial
    Kater, Arnon P.
    Van Oers, Marinus H. J. H. J.
    Norden, Yvette
    Liu, Roberto D.
    Schipperus, Martin R.
    Chamuleau, Martine
    Nijland, Marcel
    Doorduijn, Jeanette K.
    van Gelder, Michel
    Hoogendoorn, Mels
    Croon-de Boer, Fransien
    Wittebol, Shulamit
    Kerst, Martijn
    Marijt, Willem
    Posthuma, Ward
    Raymakers, Reinier
    Schaafsma, Ron
    Dobber, Johan
    Kersting, Sabina
    Levin, Mark-David
    BLOOD, 2017, 130
  • [8] Chlorambucil is still an appropriate first-line therapy for chronic lymphocytic leukaemia
    不详
    Drugs & Therapy Perspectives, 2001, 17 (20) : 8 - 12
  • [9] Lenalidomide can be safely combined with chlorambucil and rituximab in older patients with chronic lymphocytic leukemia
    Vitale, Candida
    Ferrajoli, Alessandra
    HAEMATOLOGICA, 2019, 104 (01) : 9 - 12
  • [10] Results of the Phase 3 Study of Lenalidomide Versus Placebo As Maintenance Therapy Following Second-Line Treatment for Patients with Chronic Lymphocytic Leukemia (the CONTINUUM Trial)
    Foa, Robin
    Schuh, Anna
    Zaritskey, Andrey
    Semochkin, Sergey
    Simpson, David
    Egyed, Miklos
    Vokurka, Samuel
    Kassis, Jeannine
    Zhang, Jennie
    Purse, Brendan
    Chanan-Khan, Asher A.
    BLOOD, 2016, 128 (22)
12345